Study guide

2.1 CSA Schedules I–V & Illinois Alignment

Illinois MPJE Pharmacy Jurisprudence

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Illinois MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy

2 Chapter 2: Federal Controlled Substances Foundations

2.1 CSA Schedules I–V & Illinois Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss

3 Chapter 3: Federal Drug Regulation, Privacy & Supply Chain

3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity

4 Chapter 4: IDFPR, Licensure & Eligibility

4.1 IDFPR Authority & Sources of Illinois Pharmacy Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & Experiential Requirements

5 Chapter 5: Renewal, CE, PIC & Discipline

5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 Impaired Practitioners & Mandatory Reporting

6 Chapter 6: Technicians, Interns & Supervision

6.1 Technician Registration, Training & Certification 6.2 Supervision, Scope & No Fixed Tech Ratio 6.3 Intern Scope, Delegation & Final Verification

7 Chapter 7: Prescription Authority & Validity

7.1 Who May Prescribe in Illinois 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (720 ILCS 570 + Federal) 7.4 Refills, Partial Fills & E-Prescribing Mandate

8 Chapter 8: Advanced IL Pharmacist Practice

8.1 Collaborative Practice Agreements & Clinical Services 8.2 Immunizations & Vaccine Administration 8.3 Naloxone Access & Opioid Antagonists 8.4 Drug Administration & Therapy Management

9 Chapter 9: Counseling, DUR & Patient Safety

9.1 Patient Counseling Requirements 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs

10 Chapter 10: ILPMP & Opioid Public-Health Laws

10.1 Illinois PMP Overview, Reporting & Access 10.2 Mandatory Queries, Designees & Documentation 10.3 Legitimate Medical Purpose & Red Flags

11 Chapter 11: Dispensing: Transfers, Labels & Substitution

11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine

12 Chapter 12: Pharmacy Operations & Facilities

12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Automated Systems & Self-Service Kiosks 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Delivery & Remote Services

13 Chapter 13: Compounding & Hazardous Drugs

13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Illinois Compounding Rules & Beyond-Use Dates

14 Chapter 14: Test-Day Strategy & Final Review

14.1 When Illinois Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps

2.1 CSA Schedules I–V & Illinois Alignment

Key Takeaways Explain This Topic AI

The federal Controlled Substances Act (CSA) places drugs into Schedules I–V based on accepted medical use, abuse potential, and dependence liability

Schedule I drugs have no currently accepted medical use under federal law and cannot be prescribed; Schedules II–V may be prescribed under graduated rules

Pharmacists and prescribers share corresponding responsibility for the proper prescribing and dispensing of every controlled-substance prescription

The Illinois Controlled Substances Act (720 ILCS 570) aligns with the federal five-schedule framework; Illinois may impose stricter controls

When Illinois and federal controlled-substance rules conflict, the more restrictive rule governs Illinois pharmacy practice

Last updated: November 2026

2.1 CSA Schedules I–V & Illinois Alignment

Quick Answer: The federal Controlled Substances Act (CSA) sorts drugs into five schedules by accepted medical use, abuse potential, and dependence liability. Schedule I agents have no accepted medical use and cannot be prescribed. Schedules II–V may be prescribed under rules that loosen as the schedule number rises. Pharmacists share corresponding responsibility with the prescriber. The Illinois Controlled Substances Act (720 ILCS 570) tracks this framework, and the Illinois Prescription Monitoring Program (ILPMP) captures Schedules II–V (with limited exclusions such as testosterone per ILPMP guidance). On the Illinois MPJE, apply the more restrictive rule when state and federal standards differ.

Controlled-substance law is a major MPJE weight because almost every dispensing, ordering, inventory, and diversion scenario starts with one question: what schedule is the drug, and which federal floor applies? This section builds that foundation and ties it to Illinois so later chapters on prescribing, ILPMP, and operations make sense.

Why Scheduling Exists

Congress enacted the CSA (Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970) to create a closed system of distribution . Every controlled substance should move only among DEA-registered entities and, at the end of the chain, to a patient with a valid prescription (or under another lawful exception). Scheduling is the risk classification that drives:

  • Whether a drug can be prescribed at all
  • Whether DEA Form 222 / CSOS is required to order it
  • Whether refills are allowed
  • How tightly inventory counts and security must be applied
  • How prescriptions and records must be filed

If you mis-schedule a drug on an exam vignette, every downstream answer about refills, partial fills, and ordering forms is likely wrong. Treat schedule as the first decision-tree branch.

The Five Federal Schedules

  • Schedule Medical use Abuse potential Dependence if abused Order form Typical exam examples
  • I (CI) None currently accepted High Severe 222/CSOS if handled Heroin, LSD, MDMA

II (CII) Accepted (may be restricted) High Severe physical/psychological 222/CSOS Oxycodone, hydrocodone combos, fentanyl, amphetamines, methylphenidate

III (CIII) Accepted Less than CI/II Moderate/low physical or high psychological Invoice Codeine combos (limited), buprenorphine, ketamine, anabolic steroids

IV (CIV) Accepted Less than CIII Limited relative to CIII Invoice Benzodiazepines, zolpidem, tramadol, carisoprodol

V (CV) Accepted Less than CIV Limited relative to CIV Invoice Limited codeine cough preps, pregabalin, lacosamide

Schedule I (CI)

Schedule I substances have:

  • High potential for abuse
  • No currently accepted medical use in treatment in the United States
  • Lack of accepted safety for use under medical supervision

Classic examples include heroin, LSD, MDMA (ecstasy), and peyote. Federally, marijuana in an FDA-approved drug product and marijuana subject to a state medical marijuana license have been Schedule III since April 28, 2026 (91 FR 22714); all other marijuana, including state adult-use cannabis, remains Schedule I. For the MPJE, remember: CI drugs are not prescribed or dispensed pursuant to a federal prescription. Research and certain authorized industrial uses exist under tight DEA control, but community-pharmacy practice does not lawfully stock CI for ordinary patient dispensing.

Schedule II (CII)

Schedule II substances have high abuse potential, currently accepted medical use (sometimes with severe restrictions), and abuse that may lead to severe psychological or physical dependence.

High-yield CII examples: morphine, oxycodone, hydrocodone combination products, hydromorphone, fentanyl, methadone, amphetamine, methylphenidate, cocaine (as a topical anesthetic), and certain combination products historically rescheduled into CII. CII drugs drive the strictest ordering (Form 222/CSOS), no federal refills , special partial-fill rules, and often the most careful security practices.

Schedule III (CIII)

Schedule III substances have abuse potential less than CI/CII, accepted medical use, and abuse that may lead to moderate or low physical dependence or high psychological dependence. Common examples: products containing limited codeine (for example, acetaminophen with codeine tablets at federal quantity limits), buprenorphine , ketamine, anabolic steroids, and certain barbiturate combinations. CIII prescriptions may be refilled under the federal 5-refill / 6-month ceiling (covered in depth in section 2.3).

Schedule IV (CIV)

Schedule IV substances have lower abuse potential relative to CIII, accepted medical use, and limited dependence liability relative to CIII. High-frequency exam drugs: benzodiazepines (alprazolam, diazepam, clonazepam, lorazepam), zolpidem and other Z-drugs, tramadol, carisoprodol, and phenobarbital. CIV follows the same federal refill framework as CIII (5 refills / 6 months).

Schedule V (CV)

Schedule V substances have the lowest abuse potential among controlled drugs, accepted medical use, and limited dependence relative to CIV. Examples include certain codeine-containing cough preparations within federal concentration limits, pregabalin, lacosamide, and other limited-quantity narcotic preparations. Federally, CV refill rules are more flexible than CIII/CIV (no automatic 5/6 hard cap), but Illinois reporting and practice rules still treat CV as controlled —never treat “Schedule V” as “not really controlled.”

How to Reason About an Unfamiliar Drug

Exam writers love obscure brand names. You rarely need the full FDA label. Use this pattern:

Is there accepted medical use ? If not → think Schedule I (or not a drug for prescribing).

Is it a potent opioid agonist, stimulant, or high-risk pain/ADHD agent ? → often CII.

Is it a benzodiazepine, Z-drug, tramadol, or carisoprodol ? → often CIV.

Is it buprenorphine or a limited-codeine combo ? → often CIII.

Is it a low-dose narcotic cough prep or certain anticonvulsants like pregabalin ? → often CV.

When the stem gives the schedule, trust the stem —then apply the matching federal rule set.

Corresponding Responsibility

Under federal regulation ( 21 CFR 1306.04 ), a prescription for a controlled substance must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice . The responsibility for proper prescribing and dispensing is on the prescribing practitioner , but a corresponding responsibility rests with the pharmacist who fills the prescription.

In plain language:

The prescriber must not write CS prescriptions outside legitimate practice.

The pharmacist must not knowingly dispense an invalid or illegitimate CS prescription.

“The doctor wrote it” is not a complete defense if red flags made the order clearly improper and the pharmacist ignored them.

Corresponding responsibility bridges later Illinois red-flag and ILPMP chapters. On federal-foundation items, expect scenarios such as: early refill requests with no clinical explanation, cash-paying patients traveling long distances for high-dose opioids, identical “pain” scripts from a single clinic for many unrelated patients, or prescriptions that look altered. Your job is not to diagnose the patient—it is to decide whether the order can lawfully be dispensed as a valid CS prescription.

Practical pharmacist steps when legitimacy is in doubt:

  • Verify the prescriber’s identity, DEA registration, and authority for the schedule involved
  • Contact the prescriber for clinical clarification and document the conversation
  • Check the ILPMP (required territory in Illinois practice—see chapter 10)

Refuse to fill when the prescription is not for a legitimate medical purpose or is outside usual professional practice

  • Never “partially comply” with an order you believe is forged or clearly diversionary just to avoid conflict
  • Illinois Alignment: 720 ILCS 570 and the ILPMP Overlay

Illinois’s controlled-substance framework lives primarily in 720 ILCS 570 (Illinois Controlled Substances Act), with pharmacy practice duties layered through 225 ILCS 85 and 68 Ill. Adm. Code 1330 . For MPJE purposes, treat Illinois schedules as aligned with the federal CSA architecture : the same five-schedule logic, the same idea that CI is not for ordinary prescribing, and the same principle that CII is the most tightly controlled prescribed class.

Two Illinois overlays matter even in a “federal foundations” chapter:

1) Illinois may be stricter

NABP’s MPJE does not split “federal questions” from “state questions” on the score report. If Illinois imposes a tighter refill, reporting, security, e-prescribing, or prescribing rule than the federal floor, answer under prevailing Illinois law . Federal law is the baseline; Illinois is the jurisdiction that licenses you through IDFPR.

2) ILPMP reporting covers Schedules II–V

Under Illinois PMP rules, dispensers report controlled substances to the Illinois Prescription Monitoring Program (ILPMP) . Exam-critical scope for foundations:

Schedules II, III, IV, and V are generally reportable when dispensed

ILPMP guidance excludes certain agents (notably testosterone per ILPMP site materials) and may list additional drugs of interest

Expanded query expectations continue to evolve (including statutory changes effective 1/1/2027 under PA 104-0512)—later chapters drill operational query duties

That means a technically correct federal schedule answer can still produce a wrong PMP answer if you forget that Schedule V remains controlled and reportable in Illinois. Memorize the reporting scope now so it becomes automatic.

Scheduling Changes and “Who Decides?”

Federally, scheduling authority involves the DEA and scientific/medical evaluation processes (with HHS/FDA input under the CSA framework). States can schedule or control substances under state law as well. If a drug is controlled under Illinois law even when federal status is evolving, Illinois practice and IDFPR expectations still control your conduct as an Illinois pharmacist. Exam items may mention rescheduling of a product (for example, historical hydrocodone combination product movement into CII)—use the schedule stated in the vignette and apply current rule logic for that schedule.

Connecting Schedules to Later Federal Rules (Preview)

Keep this cheat-map in your head as you move through the rest of Chapter 2:

  • Topic CI CII CIII–CIV CV
  • Ordinary Rx dispensing No Yes Yes Yes
  • DEA Form 222 / CSOS to order Yes (if handled) Yes No No
  • Federal refills N/A None ≤5 within 6 months More flexible federally

Inventory exact-count sensitivity Highest control environment Exact count rules tightest for open stock Estimate allowed if ≤1,000 units open Same estimate rule as CIII–IV

Exam Scenario: Chicago Community Pharmacy

A patient presents a handwritten prescription for “oxycodone 30 mg, #120, take 1 q6h prn pain, refill ×2” from an out-of-area clinic. The drug is CII. Even before Illinois e-prescribing and ILPMP chapters, you already know: federal law forbids CII refills , so the refill authorization is invalid on its face. You still must assess legitimacy, verify the prescriber, and apply Illinois rules—but the schedule alone killed the refill language.

Common Traps

Treating cannabis as “not controlled” because Illinois has adult-use markets— federal CI remains CI for CSA exam logic

  • Confusing CIII vs CIV refill ceilings (they share the same federal 5/6 framework)
  • Assuming Schedule V means “no PMP and no pharmacist scrutiny”
  • Answering only with the federal floor when an Illinois vignette states a stricter duty
  • Forgetting corresponding responsibility when the stem screams red flags

Master the five schedules, corresponding responsibility, and the Illinois more-restrictive-wins rule. Everything else in Chapter 2 hangs on those three anchors.